A review of cost-effectiveness analysis: From theory to clinical practice

Tafamidis—A Pricey Therapy for a Not-So-Rare Condition

(2020) Jerry H. Gurwitz et al.   JAMA Cardiology

Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease

(2019) Gregg C. Fonarow et al.   JAMA Cardiology

Association of Medicaid Expansion With Cardiovascular Mortality

(2019) Sameed Ahmed M. Khatana et al.   JAMA Cardiology

Health Care Spending in the United States and Other High-Income Countries

(2018) Irene Papanicolas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Discounting in Economic Evaluations

(2018) Arthur E. Attema et al.   PHARMACOECONOMICS

Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure

(2018) Stephen J. Greene et al.   CIRCULATION

Factors Associated With Increases in US Health Care Spending, 1996-2013

(2017) Joseph L. Dieleman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

(2016) Gillian D. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development

(2010) József Bodrogi et al.   BRITISH JOURNAL OF PHARMACOLOGY

Health outcomes in economic evaluation: the QALY and utilities

(2010) S. J. Whitehead et al.   BRITISH MEDICAL BULLETIN

Health Economic Assessment: Cost-Effectiveness Thresholds and Other Decision Criteria

(2010) Steven Simoens   International Journal of Environmental Research and Public Health

Equivalence of two healthcare costing methods: bottom-up and top-down

(2008) Michael K. Chapko et al.   HEALTH ECONOMICS